PBA
CATX icon

Paradigm Biocapital Advisors’s Perspective Therapeutics CATX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-919,692
Closed -$12.3M – 31
2024
Q3 		$12.3M Hold
919,692
– – 0.42% 32
2024
Q2 		$9.17M Buy
+919,692
New +$13.3M 0.35% 32

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Paradigm Biocapital Advisors's CATX Position: Q4 2024 in Review

Paradigm Biocapital Advisors sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 919,692 shares — an estimated $12.3M sold.

Paradigm Biocapital Advisors first reported a position in CATX in Q2 2024 and held it in 2 quarters. The position peaked at $12.3M in Q3 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

  • Paradigm Biocapital Advisors reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 919,692 Perspective Therapeutics shares in Q4 2024, an estimated $12.3M.
  • Paradigm Biocapital Advisors first reported a position in Perspective Therapeutics in Q2 2024 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Perspective Therapeutics position peaked at $12.3M in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.